AMC Entertainment Holdings

AMC · NYSE

$3.08+$0.10 (+3.36%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $2.98

AMC analyst rating

HoldConsensus of 6 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy2
Hold3
Underperform0
Sell1

12-month price target · 9 analysts

Average $3.08 (+0.1% upside)

Low: $2.22
Now: $3.08
High: $4.20

Upgrades and downgrades

The latest rating actions, newest first

AMC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Sep 25, 2026	Maintains	Sell	$1.80 → $2.20	60%
Macquarie	Sep 2, 2026	Maintains	Neutral	$2.50 → $3.00	40%
B. Riley Securities	Jul 22, 2026	Maintains	Neutral	$2.25 → $2.50	59%
Macquarie	Jul 22, 2026	Maintains	Neutral	$2.00 → $2.50	40%
Benchmark	Jul 21, 2026	Maintains	Buy	$2.50 → $3.00	54%
Wedbush	Jul 21, 2026	Maintains	Outperform	$3.00 → $4.00	56%
Macquarie	Jul 8, 2026	Maintains	Neutral	$1.50 → $2.00	40%
Citigroup	May 7, 2026	Maintains	Sell	$1.10 → $1.20	60%
Benchmark	May 6, 2026	Upgrade	Hold → Buy	$2.50	54%
Macquarie	Feb 26, 2026	Maintains	Neutral	$2.00 → $1.50	40%

The case for and against

Updated Oct 14, 2026

Bull case

AMC Entertainment Hldgs is supported by a 2Q26 beat that showed strong box office demand, with revenue of $1.597B and AEBITDA of $321.4M, both quarterly records and well above expectations, while free cash flow of $190.1M strengthened its balance-sheet repair efforts. Its outlook is further underpinned by meaningful operating leverage in a high-fixed-cost model, rising attendance in both U.S. and international theaters, and improving monetization through concessions, where domestic concessions per cap rose to $8.95 and per-attendee spend has remained about 30% above pre-pandemic levels. With no maturities until 2029, lower interest expense potential from leverage reduction, and a more favorable release slate ahead, the company appears positioned for continued margin expansion and market-share gains.

Bear case

AMC Entertainment Hldgs is viewed negatively because its earnings remain highly exposed to unpredictable, hit-driven box office results and intense competition from both rival exhibitors and alternative distribution channels, making quarterly and annual performance difficult to forecast. Its levered balance sheet and significant debt reduce financial flexibility, while depressed margins and dilution risk limit the ability to improve returns or reward shareholders. The stock also screens poorly on valuation, and the cited asset impairments and theatre closure expenses underscore ongoing operational stress and execution risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.